Amicus Therapeutics (FOLD) Scheduled to Post Quarterly Earnings on Thursday

Amicus Therapeutics (NASDAQ:FOLD) will be issuing its quarterly earnings data before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). The company had revenue of $115.08 million for the quarter, compared to analysts’ expectations of $115.11 million. Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. On average, analysts expect Amicus Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Amicus Therapeutics Stock Performance

FOLD stock opened at $10.42 on Wednesday. The company has a debt-to-equity ratio of 2.42, a current ratio of 2.88 and a quick ratio of 2.52. Amicus Therapeutics has a 1 year low of $9.70 and a 1 year high of $14.57. The company has a market cap of $3.09 billion, a P/E ratio of -20.43 and a beta of 0.80. The stock’s fifty day moving average price is $11.41 and its 200-day moving average price is $11.99.

Analyst Ratings Changes

Several research analysts have issued reports on the company. JPMorgan Chase & Co. dropped their target price on Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Monday, March 18th. Cantor Fitzgerald restated an “overweight” rating and set a $22.00 target price on shares of Amicus Therapeutics in a research report on Thursday, February 29th.

Insider Activity at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 4,167 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $14.00, for a total transaction of $58,338.00. Following the sale, the chief executive officer now owns 871,219 shares in the company, valued at approximately $12,197,066. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 4,167 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $14.00, for a total transaction of $58,338.00. Following the sale, the chief executive officer now directly owns 871,219 shares of the company’s stock, valued at $12,197,066. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Margaret G. Mcglynn sold 7,500 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $13.40, for a total value of $100,500.00. Following the completion of the transaction, the director now directly owns 59,289 shares of the company’s stock, valued at approximately $794,472.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,208 shares of company stock worth $732,930. 2.20% of the stock is owned by company insiders.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.